Cervical cancer trial pulled before it started

NCT ID NCT06866951

Terminated Disease control Sponsor: Women's Hospital School Of Medicine Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to compare chemo-immunotherapy (chemotherapy plus a PD-1 inhibitor) against standard chemoradiotherapy for cervical cancer patients whose cancer had spread to lymph nodes after surgery. The goal was to see which approach better prevented cancer from returning or spreading. However, the trial was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Chemo-immunotherapy (paclitaxel, cisplatin/carboplatin, and PD-1 inhibitor)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER WITH LYMPH NODE METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCERS

Contacts and locations

Locations

Womens' Hosptial, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.